About

NaviGate Cardiac Structures, Inc.

NaviGate Cardiac Structures, Inc., (NCSI) is an early-stage company focused on developing transcatheter solutions for the treatment of atrioventricular valve regurgitation. The NaviGate valve-based technology was licensed from Cleveland Clinic and further modified and developed by NCSI.

The GATE™ Valve

The NCSI Team

The leadership team at NCSI includes a core group of professionals with considerable experience and expertise in the development of surgical and transcatheter replacement heart valves. You can learn more about NCSI’s leadership team below.

Peter W. J. Hinchliffe

CEO

Previously; Director of R&D, United States Surgical Corp. (now Medtronic), Founder and VP of R&D, Rex Medical (start-up), President and CEO Datascope Corp., Vascular Interventions, President and CEO Getinge Cardiac Systems, Jarvik Heart President and COO. Over 30 years of Medical Device Experience with over 100 issued US medical device patents and over 100 more pending.

R.C. Quijano

Chief Technology Officer

Neville Jeharajah – CFO & Acting Director of Operations Supply Chain, HR. VP Finance and Operations, Edwards Heart Valves; Baxter Healthcare Corp, Corporate Financial Planning, and Corporate Officer; Strategic and Operational Planning. Over 25 years experience.

Thomas Humphrey

Global VP of Regulatory Affairs and Quality Assurance

Thomas Humphrey – Global VP of Regulatory Affairs and Quality Assurance – With more than three decades of experience focusing on cardiovascular medical devices, Mr. Humphrey’s experience in the medical device industry has included responsibility for Regulatory, Quality and Clinical Affairs for surgical and transcatheter heart valve programs. Prior to joining Navigate Cardiac Structures, Inc., Mr. Humphrey served as Director of Regulatory, Quality and Clinical Affairs at 3F Therapeutics, Inc. and Director of Regulatory Affairs at Edwards Lifesciences LLC.

Kalathi Thyagarajan

Vice President, Clinical Affairs

Kalathi Thyagarajan, Vice President, Clinical Affairs with 30+ years of experience in Biological Heart Valves in various manufacturers, including Meadox Medical (Shelhigh Valves), Edwards Cardiovascular Surgery, VenPro, Director of Research; 3F Therapeutics, CoreValve Percutaneous Aortic Valve V.P., RA/QA and CardiAQ Valve Technologies, VP RA/QA.

Matthew Pollman

Executive Vice President

Matthew Pollman, M.D., Executive Vice President, Founder/President/CSO CV Ingenuity; Medical Director Abbott Vascular; Director New Ventures Guidant; Director Cardiovascular Biology Millennium Pharmaceuticals. Over 25 years of experience.